Oklahoma City biotech firm to begin sickle cell anemia drug trial
Selexys Pharmaceuticals Corp. is ready to begin testing its sickle cell disease drug with patients.Published: Tuesday, August 20, 2013 By: Staff Reports Source: The Oklahoman
Selexys Pharmaceuticals Corp. is enrolling patients in a Phase 2 trial of a drug designed to treat sickle cell disease.
The Oklahoma City-based company obtained $23 million in venture capital financing last fall to help pay for clinical study.
Selexys' study will include about 175 patients nationwide. Patients randomly will receive a high dose of Selexys' SelG1 or a placebo, with or without standard treatment.